The association of sildenafil and sexual function in women with pulmonary arterial hypertension associated with congenital heart disease: Subanalysis of the COHARD-PH registry

Globally, approximately 1% of live births are associated with congenital heart disease (CHD), representing the most common congenital abnormality. Roughly 10% of adult CHD patients suffer from pulmonary arterial hypertension (PAH), a condition that may progress to right heart failure and mortality if untreated. Sildenafil is frequently prescribed for PAH; however, its effects on sexual function in patients with CHD remain poorly studied. We performed an observational study employing a retrospective cohort design to evaluate clinical data from patients with CHD treated at Sardjito Hospital, Yogyakarta, between January 2019 and July 2025. Study participants were stratified into two groups, consisting of those receiving sildenafil therapy and those not treated with sildenafil. Eligible participants were required to have been sexually active within the preceding four weeks. Sexual function in both treatment groups was evaluated using the Female Sexual Function Index (FSFI) questionnaire. As many as 78 subjects met the criteria and completed the FSFI questionnaire. Fifty-seven and 21 participants were assigned to the sildenafil-exposed group and to the non-exposed group, respectively. Among those receiving sildenafil, 35.1% (20 patients) experienced sexual dysfunction, while 64.9% (37 patients) had normal sexual function. Bivariate analysis revealed a significant relationship between sildenafil use and sexual dysfunction in the study subjects (p=0.033; 95% CI 0.12-0.94). Multivariate analysis revealed that sildenafil consumption was linked to a lower occurrence of sexual dysfunction (OR 0.13; p=0.005; 95% CI 0.03-0.53). To conclude, sildenafil therapy in women with PAH-CHD was associated with reduced likelihood of sexual dysfunction.

Authors

Institutions

Publication Details

Journal
Journal of Cardiovascular Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.1097/fjc.0000000000001900
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The association of sildenafil and sexual function in women with pulmonary arterial hypertension associated with congenital heart disease: Subanalysis of the COHARD-PH registry

Bernadus Bernardino Bramantyo, Lucia Kris Dinarti, Dyah Wulan Anggrahini, Alifiani Ismawardika et al.
Journal of Cardiovascular Pharmacology
Pulmonary Hypertension Research and Treatments
article

The association of sildenafil and sexual function in women with pulmonary arterial hypertension associated with congenital heart disease: Subanalysis of the COHARD-PH registry

Bernadus Bernardino Bramantyo, Lucia Kris Dinarti, Dyah Wulan Anggrahini, Alifiani Ismawardika, Anggoro Budi Hartopo, Putrika Prastuti Ratna Gharini, Cindy Elica Cipta
article en

Abstract

Globally, approximately 1% of live births are associated with congenital heart disease (CHD), representing the most common congenital abnormality. Roughly 10% of adult CHD patients suffer from pulmonary arterial hypertension (PAH), a condition that may progress to right heart failure and mortality if untreated. Sildenafil is frequently prescribed for PAH; however, its effects on sexual function in patients with CHD remain poorly studied. We performed an observational study employing a retrospective cohort design to evaluate clinical data from patients with CHD treated at Sardjito Hospital, Yogyakarta, between January 2019 and July 2025. Study participants were stratified into two groups, consisting of those receiving sildenafil therapy and those not treated with sildenafil. Eligible participants were required to have been sexually active within the preceding four weeks. Sexual function in both treatment groups was evaluated using the Female Sexual Function Index (FSFI) questionnaire. As many as 78 subjects met the criteria and completed the FSFI questionnaire. Fifty-seven and 21 participants were assigned to the sildenafil-exposed group and to the non-exposed group, respectively. Among those receiving sildenafil, 35.1% (20 patients) experienced sexual dysfunction, while 64.9% (37 patients) had normal sexual function. Bivariate analysis revealed a significant relationship between sildenafil use and sexual dysfunction in the study subjects (p=0.033; 95% CI 0.12-0.94). Multivariate analysis revealed that sildenafil consumption was linked to a lower occurrence of sexual dysfunction (OR 0.13; p=0.005; 95% CI 0.03-0.53). To conclude, sildenafil therapy in women with PAH-CHD was associated with reduced likelihood of sexual dysfunction.

Journal of Cardiovascular Pharmacology
Universitas Gadjah Mada (ID)
Good health and well-being
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon